[Music] We are following this breaking news impacting President Trump's immigration policy. In just the last hour here in New Hampshire, a federal judge issued a nationwide block against the president's order to end birthright citizenship. So that judge granted the plaintiff's bid for class action status, but ruled that the protected class does not include the parents of the children whose citizenship would be threatened.Last month, the Supreme Court limited the power of lower courts to issue nationwide inj ...

Democrats in Congress are slamming the Supreme Court's ruling in the birthright citizenship case. Our next guest, Democratic Congressman Jamie Raskin, wrote on X, "Eager to sue Trump's wounded ego, the Supreme Court ended nationwide injunctions. Trump is crowing, but this is this just means we'll take our smashing wins in four district courts and turn them into wins in 94 district courts. People born here are citizens, period." Ranking member on the House Judiciary Committee, Congressman Jamie Rascin joins ...

Core Viewpoint - The Schall Law Firm is investigating Quipt Home Medical Corp. for potential violations of securities laws, particularly concerning misleading statements and failure to disclose important information to investors [1][2]. Group 1: Investigation Details - The investigation centers on whether Quipt issued false or misleading statements, particularly regarding a press release on May 21, 2025, related to an acquisition offer from Forager Capital Management [2]. - Forager Capital Management, a significant shareholder, has requested Quipt to retract its misleading statement about their offer to acquire 100% of Quipt's common shares at a price of $3.10 per share [2]. - Following the news of the investigation and the press release from Forager, Quipt's shares experienced a decline of over 8.5% on the same day [2]. Group 2: Legal Representation - The Schall Law Firm is representing investors globally and specializes in securities class action lawsuits and shareholder rights litigation [3]. - Shareholders who have suffered losses are encouraged to contact the Schall Law Firm for a free discussion of their rights [3].

Core Viewpoint - The Schall Law Firm is investigating Bausch + Lomb Corporation for potential violations of securities laws, focusing on misleading statements and undisclosed information that may have affected investors [1][2]. Financial Performance - Bausch + Lomb reported an adjusted net loss of $54 million for Q1 2025, a significant decline compared to a net income of $24 million in the same period of the previous year [2]. - The company has lowered its full-year growth outlook, attributing part of this change to the recall of its enVista product [2].

Core Viewpoint - The Schall Law Firm is investigating OneStream, Inc. for potential violations of securities laws, focusing on whether the company made false or misleading statements or failed to disclose important information to investors [1]. Group 1 - The investigation is aimed at protecting the rights of investors who may have suffered losses due to the company's actions [1]. - The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation, representing investors globally [2].

LOS ANGELES, May 8, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of SelectQuote, Inc. ("SelectQuote" or "the Company") (NYSE: SLQT) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. SelectQuote is the subject of a DOJ False Claims Act filed on May 1, 2025. The f ...

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. ICU Medical is the subject of an FDA warning letter published on April 22, 2025. According to the government agency, the Company "made multiple changes to the Medfusion Model 4000 Syringe Infusion Pump and CADD Solis VIP Ambulatory Infusion Pump that could significantly affect the safety or effectiveness of these devices." The FDA states that the Company's ...